320 related articles for article (PubMed ID: 27537201)
1. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).
Oliveira EF; Santos-Martins D; Ribeiro AM; Brás NF; Cerqueira NS; Sousa SF; Ramos MJ; Fernandes PA
Expert Opin Ther Pat; 2016 Nov; 26(11):1257-1272. PubMed ID: 27537201
[TBL] [Abstract][Full Text] [Related]
2. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
Pfefferkorn JA
Expert Opin Ther Pat; 2011 Feb; 21(2):187-203. PubMed ID: 21214503
[TBL] [Abstract][Full Text] [Related]
3. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
Wojakowski W; Gmiński J
Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
[TBL] [Abstract][Full Text] [Related]
4. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Davidson MH
Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
[TBL] [Abstract][Full Text] [Related]
5. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
Pfefferkorn JA
Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
[TBL] [Abstract][Full Text] [Related]
6. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Duplaga BA
Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
[TBL] [Abstract][Full Text] [Related]
7. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Rackley CE
Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
Essig M; Vrtovsnik F; Friedlander G
Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
[TBL] [Abstract][Full Text] [Related]
9. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
MacNeil P
Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
[TBL] [Abstract][Full Text] [Related]
10. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
11. Effects of statin therapy on the progression of chronic kidney disease.
Shah S; Paparello J; Danesh FR
Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
[TBL] [Abstract][Full Text] [Related]
12. HMG CoA reductase inhibitors.
Feussner G
Curr Opin Lipidol; 1994 Feb; 5(1):59-68. PubMed ID: 15559032
[TBL] [Abstract][Full Text] [Related]
13. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
Pallottini V
Expert Opin Ther Pat; 2015; 25(10):1079-83. PubMed ID: 26135220
[TBL] [Abstract][Full Text] [Related]
14. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
Fujita R; Matsushima T
Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
Baskaran G; Salvamani S; Ahmad SA; Shaharuddin NA; Pattiram PD; Shukor MY
Drug Des Devel Ther; 2015; 9():509-17. PubMed ID: 25609924
[TBL] [Abstract][Full Text] [Related]
16. An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia.
Gesto DS; Pereira CMS; Cerqueira NMFS; Sousa SF
Molecules; 2020 Aug; 25(17):. PubMed ID: 32859023
[TBL] [Abstract][Full Text] [Related]
17. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.
Chong PH
Ann Pharmacother; 2002 Dec; 36(12):1907-17. PubMed ID: 12452755
[TBL] [Abstract][Full Text] [Related]
18. The safety of statins in children.
Lamaida N; Capuano E; Pinto L; Capuano E; Capuano R; Capuano V
Acta Paediatr; 2013 Sep; 102(9):857-62. PubMed ID: 23631461
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology of statins.
Sirtori CR
Pharmacol Res; 2014 Oct; 88():3-11. PubMed ID: 24657242
[TBL] [Abstract][Full Text] [Related]
20. A general assessment of the safety of HMG CoA reductase inhibitors (statins).
Black DM
Curr Atheroscler Rep; 2002 Jan; 4(1):34-41. PubMed ID: 11772420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
